Two great articles from the National Institute of Health (NIH) and Minyanville that talk about Cordyceps and how Pharmaceutical companies will generate billions from this powerful herb. Contact Hannah Tran at firstname.lastname@example.org for a Ageloc Vitality Cordyceps
“Back in September, the New York Times reported that bringing Gilenya to market would be a boon to Novartis, who had been competing with Merck to be the first company to release an oral MS drug.
So what’s the science behind this fungal discovery? Bloomberg reports:
“The scientists began studying in 1986 the Cordyceps fungus known in Chinese and Japanese as “winter insect, summer plant,” so called because it invades insect larva during winter and grows out of the host by summer.
Fujita said he was inspired by the discovery of ciclosporin, also derived from a fungus, which spurred research into how the immune system may be subdued in transplant patients. Fujita, now a professor emeritus at Kyoto University, said he was unaware the immune-modulating properties of Cordyceps could eventually help multiple sclerosis patients.”
“This study aimed to evaluate the ability of the health food supplement Cordyceps sinensis (CS) to ameliorate suppressive effects of chemotherapy on bone marrow function as a model for cancer treatment….”